Quob Park Estate Ltd signed a letter of intent to acquire 70% stake in Aiomed GmbH from Biosign Technologies Inc. (TSXV:BIO) for €3.2 million on January 21, 2016. Pursuant to the letter of intent, Biosign Technologies agreed to sell the Aiomed shares in exchange for receipt of €1.36 million in shares of Quob Park Estates, €1 million repayment against the loan payable by Aiomed to Biosign on or before November 30, 2016 and loan notes of €0.87 million to Aiomed to repay a debt to the founder of Aiomed on or before August 31, 2016. In addition, Quob Park Estates has agreed to provide loans to Biosign up to €0.65 million to fund Biosign operations for the period up to the date of a special shareholder meeting required to approve the divestiture transaction.

In a related deal, Biosign Technologies Inc. (TSXV:BIO) agreed to purchase additional 36.5% stake in Aiomed GmbH from the founder in stock on January 21, 2016. If the divestiture transaction is approved by shareholders, Biosign's remaining ownership will represent 5% of the issued and outstanding shares of Aiomed. The transaction is subject to finalizing a purchase and sale agreement and obtaining regulatory and shareholder approval of Biosign Technologies. The currency has been converted from www.oanda.com as of January 21, 2016.